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ABSTRACT  
Aim of this study is to develop chewable tablets of Syzygium cumini seed powder. It has been chosen to do so as there are no oral solid dosage 
forms of this seed powder developed so far. There are numerous health benefits and nutrient properties of this seed powder, thus it can be used 
as a nutraceutical. Phytochemical screening of the Syzygium cumini seed powder has been conducted and the various phyto constituents 
present were detected. Seven different formulations have been developed by direct compression method out of which five were optimized. All 
these formulations were developed with Syzygium cumini seed powder as the active ingredient and lactose, acacia, glucose, talc, magnesium 
stearate, hydroxy propyl methyl cellulose, sodium alginate, guar gum and stevia were used as excipients. Various evaluations tests were 
performed to check the stability of the chewable tablets. Fourier Transform Infrared Spectroscopy (FTIR) analysis was conducted to check the 
interactions among the seed powder and the excipients. Anti-bacterial activity of the chewable tablets was tested against three different species 
of bacteria (Escherichia coli and Bacillus subtilis) by agar diffusion method. It is concluded that the Syzygium cumini seed powder and the 
developed chewable tablets were active against Escherichia coli and Bacillus subtilis.     
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Syzygium cumini, commonly known as jambolan, Java plum, 
black plum or jamun, is an evergreen tropical tree in the 
flowering plant family Myrtaceae. It is native to the Indian 
Subcontinent, adjoining regions of Southeast Asia, China and 
Queensland. The name of the fruit is sometimes 
mistranslated as blackberry, which is a different fruit in an 
unrelated order[1]. The seed of the fruit is used in various 
alternative healing systems like Ayurveda, Unani and 
Chinese medicine. Various phytochemical compounds 
identified in Syzygium cumini seed powder are tabulated in 
table 1. Wine and vinegar are also made from the fruit and it 
is also a high source in vitamin A and vitamin C[2]. The seed 
powder is reported to have nutraceutical properties[3], as it 
contains significant amounts of carbohydrates, proteins, fats, 
fiber, calcium and phosphorus[2] and other parts of this 
plant like leaves were reported to have anti-platelet[4], anti-
coagulant[5], anti-hypertriglyceridemic effect[6], anti-
inflamatory[7] properties and anti-diabetic activity[8-10]. 
Syzygium cumini seed powder is composed of phenols, 
tannins, which are mainly responsible for the antimicrobial 
activity of the seed powder. The seed powder is active 
against various species of microbes like E. coli, Bacillus 
subtilis, Streptococcus and Staphylococcus[11, 12] 
Despite its overwhelming potential, to the best of our 
knowledge, there are no formulations of Syzygium cumini 
seed powder reported. Goal of the present study is to 
develop chewable tablets of seed powder of syzygium cumini. 
Chewable tablets are more stable compared to liquid dosage 
forms, and as they start disintegrating in the oral cavity and 
slowly release the drug, the active components of the see 
powder in this case, and elicit its anti-bacterial activity 
against the bacteria residing in the oral cavity, such as E. coli, 
Bacillus subtilis, Streptococcus and Staphylococcus, 
Pseudomonas, Lactobacillus and Atopobium species. Seven 
different chewable tablet formulations were prepared by 
changing the tablet composition and the formulations were 
subjected to quality control tests including weight variation, 
hardness, friability, disintegration. Antibacterial activity of 
the formulations was tested against E. coli and Bacillus 
subtilis.
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Table 1: Phytochemical compounds identified in Syzygium cumini seed powder 
S. No Class of metabolite Compounds identified 
1 Flavonoids Quercetin, rutin, 3,5,7,4-tetrahydroxy flavanone 
2 Phenolic acids Caffeic acid, ellagic acid, ferulic acid, gallic acid 
3 Tannins HHDP-galloyl glucose, trigalloyl glucose 
4 Terpenes Citronellol, geraniol, hotrienol, nerol, β-phenylethanol, phenylpropanal 
5 Anthocyanins Cyanidin, delfinidin, petudinin 
 
MATERIALS & METHODS 
Materials 
Seeds from the domestically grown Syzygium cumini plant 
were collected, shade dried, powdered and sieved. The 
authentication of the plant was obtained from Botanical 
Survey of India (BSI), Deccan Regional Centre, Hyderabad, 
India. Stevia powder was purchased from The Herbs N 
Spices, Neemuch, Madhya Pradesh, India. Lactose, acacia, 
glucose, talc, magnesium stearate, Hydroxy Propyl Methyl 
Cellulose (HPMC), sodium alginate, guar gum, polyethylene 
glycol (PEG) 400, dichloromethane and ethanol were 
purchased from S.D Fine Chem Ltd. Mumbai, Maharashtra, 
India.  
Methods 
Phytochemical Screening: The seed powder was subjected 
to phytochemical analysis by performing tests for alkaloids, 
cardiac glycosides, flavonoids, steroids/triterpenoids, 
tannins and phenols and saponins as reported 
previously[13]. 
Formulation of chewable tablets of Syzygium cumini 
seed powder: Tablets were formulated by direct 
compression method[14-16]. Seven formulations were 
formulated with constant amount of seed powder and varied 
concentrations of excipients as shown in table 3. The 
excipients and the seed powder were added into a mortar-
and-pestle in the decreasing order of their weights, mixed 
thoroughly and the powder was evaluated for angle of 
repose, bulk density, tapped density and Carr’s index which 
are tabulated in table 2. Chewable tablets were formulated 
using R & D scale tablet punching machine 
(Karpatavastatinvati Engineering Ltd.).    
Pre-Compression evaluation[14]: 
Angle of repose: The angle of repose of the powder blend 
was calculated using funnel method[17]. A known amount of 
the powder blend was placed in a glass funnel. The height of 
the funnel was adjusted in such a way that the tip of the 
funnel just touched the apex of the powder blend. The 
powder blend could flow through the funnel freely. Diameter 
of the powder pile was measured, and angle of repose was 
calculated using the following equation[17]. 
Tanθ=h/r 
Where Tanθ is the angle of repose; h is the height and r is the 
radius of the powder mass  
Determination of Bulk density and Tapped density: A 20 
mg of the powder was placed into a 100 mL measuring 
cylinder and the initial volume was observed. The cylinder 
could fall onto a hard surface from the height of 2.5 cm with 
a time interval of 2 sec. Tapping was continued until no 
further change in volume was noted. The bulk density and 
tapped density were calculated using the following 
formula[14]: 
Bulk density = W/Vo; Tapped density = W /VF 
Where W =weight of the powder; Vo =initial volume of 
powder; VF = Final volume of powder 
The ratio of the tapped density to the bulk density is called 
Hausner’s ratio. Hausner’s ratio >1.25 indicates good 
flowability of the powder. 
Compressibility Index: Compressibility index or Carr’s 
index is an important measure that can be obtained from the 
bulk and tapped density. It is calculated by the equation, 
Carr’s index = (Tapped density – Bulk density)/Tapped 
density. For a material to be more flowable it needs to be 
less compressible. A material having value of less than 20% 
has good flow properties[14]. 
Quality control tests for tablets:  
Weight variation: Weight variation test is done by weighing 
20 tablets individually. The average  tablet weight was 
calculated and compared with the individual weigh. This 
procedure has been followed as per USP.   
Tablet hardness: The resistance of tablets to break under 
conditions of storage, transportation and handling before 
usage depends on tablet’s hardness. The hardness of each 
batch was tested by randomly testing the tablets (how many 
per batch) using Monsanto hardness tester (Make: Pharma 
Chem Machineries). The hardness was measured in terms of 
Kg/cm2. 
Friability: The device subjects the tablets to abrasion and 
shock by utilizing a plastic chamber that revolved at 25 rpm. 
Sample of 10 tablets, whose weight is measured previously, 
were dropped in the friabilator from a distance of 6 inches 
which was then operated for 100 revolutions and the tablets 
were dusted and reweighed[14]. According to USP, to pass 
the test, the tablet should not lose more than 1% of their 
weight. 
% friability = [(W1-W2)/W1] *100 
Where W1= Weight of tablets before test 
W2= Weight of tablets after test 
Disintegration Test: Disintegration test was conducted by 
using USP II Disintegration test apparatus. One tablet is 
placed in each tube and the basket rack was positioned in a 
1-litre beaker of water at 37±20C. A standard motor-driven 
device is used to move the basket assembly containing the 
tablets up and down through a distance of 5 to 6 cm at a 
frequency of 28 to 32 cycles per minutes. The time taken for 
the tablet to disintegrate completely was recorded. 
Determination of Anti-bacterial activity: Agar well 
diffusion method was adopted for calculating the zone 
inhibited by the formulated chewable tablets[18, 19]. In this 
method, glassware was sterilized in a hot air oven at 1600C 
for one-hour, nutrient media was prepared and autoclaved 
at 1200C for 20min. Cool the media and allowed it to solidify. 
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The culture was inoculated by pour plate method and a bore 
was made at the center using a sterile borer, in which the 
formulation was placed, this process should be carried out in 
an aseptic chamber. The nutrient medium was incubated at 
370C for 24 hours followed by the measurement of the zone 
of inhibition by the zone reader. 
RESULTS AND DISCUSSION:  
Phytochemical Screening: Phyto constituents like 
alkaloids, cardiac glycosides, flavonoids, steroids, tannins 
and phenols were found to be present whereas saponins 
tested to be absent. The results are depicted in table 2.
 
Table 2: Phytochemical screening of Syzygium cumini seed powder 
Phyto constituents like alkaloids, cardiac glycosides, flavonoids, steroids, tannins and phenols were found to be present 
whereas saponins were tested to be absent. 
S. No Test  Result 
1 Detection of alkaloids:  
1) Mayer’s Test 
2) Dragendroff’s test  
3) Wagner’s Test  





2 Detection of Cardiac glycosides: 
1) Kedde’s test  
2) Baljet’s test   
+ 
+ 
3 Detection of flavonoids:  
1) Shinoda Test  
+ 
4 Detection of saponins:  
1) Froth Formation test 
- 
5 Detection of steroids/ 
Triterpenoids:  
1) Salkowski test  
2) Sulphur powder test  




6 Detection of tannins + 
7 Detection of Phenols + 
 
Preparation and evaluation of chewable tablets:  
Chewable tablets of syzygium cumini seed powder have been 
prepared by direct compression method, depicted in figure 1. 
The composition of these chewable tablets is shown in table 
3. Lactose was used as a diluent to increase the bulk of the 
powder mixture. Acacia acts as a binding agent which holds 
the powder material together by adhesion or cohesion.  To 
mask the taste of the seed powder, glucose was used as a 
sweetening agent. Talc was incorporated as a glidant and 
magnesium stearate was used as a lubricant. While the 
powder mixture was compressible directly without adding 
the binder, the tablets were unstable separating into layers 
(also called lamination of the tablet). When 50 mg (10%) of 
the he binding agent was incorporated, the hardness of the 
resulting tablets was poor (<1 kg/Cm2), which might be due 
to insufficient binder. To improve the stability of the tablets, 
the binder concentration was further increased to 17% 
keeping the quantity of other excipients constant. A total of 
seven formulations were made using R & D scale tablet 
punching machine (Karpatavastatinvati Engineering Ltd.). 
Color, weight variation, hardness, friability, thickness and 
disintegration time were evaluated and the data are 
presented in table 4.   
All the evaluations tests have been performed from F3 
through F7 as F1 and F2 failed in the pre-formulation stage 
itself. The physical appearance of the tablets was smooth and 
uniform with no cracks and with a diameter of 1 cm. To 
ensure each tablet contains desired amount of seed powder, 
weight variation test was conducted. The tablets met the USP 
specifications that not more than 2 tablets are outside the 
percentage limit which is ±5%. All the tablets were within 
±10% variation from the average weight of the formulation.  
Friability is generally referred to loss in weight of tablet in 
the containers due to removal of fines from the tablets 
surface. Friability generally reflects poor cohesion of tablets 
ingredients. Friability test was performed with 10 tablets of 
each formulation. The average weight loss of the tablets 
following friability testing was with 1% of the average 
weight of the formulation indicating the physical stability of 
the tablets when exposed to mechanical shock and attrition. 
Hardness test was performed to provide a measure of the 
tablet’s strength as the tablets need to be hard enough for 
packing and moving, but no so hard creating difficulty during 
chewing. The hardness ranged from 2.5 to 3.0 kg/cm2. 
Thickness of the tablets was found to be from 0.76 to 0.78 cm 
from F3 to F7 which might affect disintegration.  
Disintegration time of chewable tablets should be short 
enough to prevent choking in case the patient does not 
completely chew it. Six tablets were tested for disintegration 
from each formulation. The disintegration time of the tablets 
ranged from 22 to 25 min. All the formulations F3 to F7 have 
been show to stable and meet the United States 
Pharmacopoeia (USP) quality control standards for chewable 
tablets. It should be noted, however, that in F6 stevia was 
used to replace glucose, which makes it suitable for diabetic 
patients. The formulation F7 has a coloring agent to improve 
its aesthetic appeal. The results of all the evaluation tests 
have been tabulated in table 5.  
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Figure 1: Chewable tablets of Syzygium cumini seed powder 
Seven different formulations of chewable tablets were developed and evaluated.  
Table 3: Flow Properties of formulation for chewable tablets 
All the pre-formulation evaluation test parameters have been tested and the flow was infered to be excellent. Chewable tablets 
were formulated as the powder blend had excellent flow properties. 
S. No Evaluation test Test values 
1 Bulk density 0.107gm/ml 
2 Tapped density 0.110gm/ml 
3 Angle of repose 26.5 
4 Husner’s ratio 1.1 
5 Car’s index 7.69 
 
Table 4: Formulations of chewable tablets 
Seven different formulations (F1 to F7) have been formulated with varying amounts of excipients but the quantity of the seed 















Seed powder 200 200 200 200 200 200 200 
Lactose 200 200 250 250 250 250 250 
Acacia - 50 100 100 100 100 100 
Glucose 10 10 - 10 10 - - 
Talc 05 05 05 05 05 05 05 
Stevia - - - - - 10 10 
Magnesium stearate 05 05 05 05 05 05 05 
Colorant - - - - q.s(turmeric) - q.s(orange) 
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Table 5: Evaluation of chewable tablets 
Evaluation tests have been performed for five formulations, F3 to F7. Color of the F7 tablets were observed to be orange and 
that of F5 were pale yellow due to the presence of colorant. Although F4, F6 and F7 found to be the hardest tablets, F3 and F5 
formulations too were hard enough. Tablets of F5 were the thickest and that of F3 had the least thickness. All the formulated 
tablets had uniform diameter whereas the disintegration time varied from 22min to 25min. No evaluation tests have been 
conducted for F1 and F2 as they did not turnout well during the formulation itself.             
Parameter F1 F2 F3 F4 F5 F6 F7 
Color Lamination was 
observed. This 
may be due to 





Buff  Buff Pale yellow  Buff Orange  
Weight 
variation 
  P P P P P 
Hardness    2.5±0.1 3.0±0.1 2.8±0.2 3.0±0.1 3.0±0.2 





0.77±0.01 0.78±0.01 0.77±0.01 0.77±0.01 
Disintegration 
time(min) 
  25±0.5 23±0.5 22±0.5 22±0.3 23±0.5 
Diameter (cm)   1 1 1 1 1 
 
 
Interaction between the seed powder and the excipients 
of the tablet 
Fourier Transform Infrared Spectroscopy (FTIR) studies 
were performed to determine the interactions between the 
active ingredient[20] i.e. Syzygium cumini seed powder and 
the excipients present in the chewable tablets, if any. FTIR 
spectra the pure Syzygium cumini seed powder and 
chewable tablet powder blend are shown in Fig 2 and 3, 
respectively. It should be noted that the characteristic peaks 
in the FTIR spectra of the seed powder or the tablet 
excipients were not altered, indicating that there are no 
interactions between the active ingredient and the 
excipients used for formulating chewable tablets. Although 
the sharpness and wavelength were found to be different, 
but the peaks were in the same frequency range. 
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FTIR of the plain seed powder has been performed and it has been compared with that of the chewable tablet powder blend.  
 
Figure 3: FTIR of Syzygium cumini chewable tablet 
 
When the FTIR of the seed powder is compared to that of the 
chewable tablet blend it was observed there were no 
interactions between the seed powder of Syzygium cumini 
and the excipients of the chewable tablet.  
In vitro antibacterial activity against Escherichia coli and 
Bacillus subtilis.  
The crude seed powder of Syzygium cumini and the 
formulated chewable tablets were tested for antibacterial 
activity against Escherichia coli and Bacillus subtilis using 
agar diffusion method[18] and the results are observer 
results are shown in figures 4 & 5. It has been chosen to 
perform antibacterial study against Escherichia coli and 
Bacillus subtilis as these are the bacteria which usually reside 
in the gut, also in the oral cavity, to some extent, of humans. 
As it has been formulated as chewable tablets, disintegration 
starts in the mouth itself which might show its antibacterial 
effect against the bacteria residing in the oral cavity. Both the 
crude seed powder and the tablet showed significant 
antibacterial activity against Escherichia coli and Bacillus 
subtilis, whose results are represented in table 6. Zone of 
inhibition was measured using a zone reader and it can be 
inferred that Syzygium cumini seed powder contains 
constituents that are responsible for antibacterial activity. 
The zone of inhibition for Eschericia coli was found to be 3.2 
cm and the zone of inhibition for Bacillus subtilis was found 
to be 2.7 cm. Data clearly show that our formulation have 
antimicrobial activity against both Escherichia coli and 
Bacillus subtilis.  
 
Figure 4: Anti-bacterial activity of Syzygium cumini 
chewable tablet against Escherichia coli 
It can be clearly observed that the chewable tablet is active 
against Escherichia coli. Zone of inhibition was measured to 
be 3.2cm.  
 
Figure 5: Anti-bacterial activity of Syzygium cumini 
chewable tablet against Bacillus subtilis. 
It can be clearly observed that the chewable tablet is active 
against Bacillus subtilis. Zone of inhibition was measured to 
be 2.7cm 
 
Table 6: Antibacterial activity of Syzygium cumini 
The anti-bacterial activity of both the seed powder and the developed chewable tablets have been tested against three different 
species of bacteria. Among the three bacteria, both tablets and seed powder showed more activity against Escherichia coli while 
no activity was observed against Staphylococcus aureus.  
S. No Test component Quantity 
(mg) 
    Zone of inhibition (cm) 
Escherichia coli Bacillus subtilis 
1 Chewable tablet 570 3.2 2.7 
2 Seed powder 200 3.4 2.8 
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CONCLUSION:  
Chewable tablets of Syzygium cumini seed powder were 
formulated and evaluated. Preformulation studies were done 
to optimize the composition of the tablet powder blend. The 
FTIR studies showed that there is no interaction between the 
seed powder and the tablet excipients. The antimicrobial 
studies revealed that the formulation is having antimicrobial 
activity against E. coli and B. Subtlis. The chewable tablet 
formulation has the potential to be used as a nutraceutical. 
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